Wednesday, July 8, 2026

Intelligence · Clinical Development

Pipeline search results

Programs matching “acute-myeloid-leukemia” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.

Matching programs 134
Total indexed 20,548
Sponsors 1,769

Quick answer

Showing 134 pipeline programs matching "acute-myeloid-leukemia" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.

Refine search

134 results for “acute-myeloid-leukemia” Back to intelligence hub

Search results

Page 1 of 6
  1. Arsenic trioxide

    Teva Pharma GmbH

    Acute Myeloid Leukemia

    phase 3 small molecule terminated

    1 trial
  2. Asparaginase

    Children's Hospital of Fudan University

    Acute Myeloid Leukemia

    phase 3 small molecule active

    1 trial
  3. Azacitidine Combined With Venetoclax and ATRA group

    The First People's Hospital of Lianyungang

    Acute Myeloid Leukemia

    phase 3 small molecule active

    1 trial
  4. CPX-351

    Jazz Pharmaceuticals Ireland Limited

    High Risk Acute Myeloid Leukemia

    phase 3 small molecule completed

    1 trial
  5. Cytarabine

    Jazz Pharmaceuticals Ireland Limited

    Acute Myeloid Leukemia

    phase 3 small molecule active

    1 trial
  6. DAC-HAAG-02

    Hospital Authority, Hong Kong

    Acute Myeloid Leukemia

    phase 3 small molecule active

    1 trial
  7. Decitabine

    The First People's Hospital of Lianyungang

    Acute Myeloid Leukemia

    phase 3 small molecule active

    1 trial
  8. Decitabine

    The First People's Hospital of Lianyungang

    Acute Myeloid Leukemia, Adult

    phase 3 small molecule active

    1 trial
  9. Decitabine plus HAAG regimen

    The First People's Hospital of Lianyungang

    Acute Myeloid Leukemia

    phase 3 small molecule active

    1 trial
  10. Dociparstat

    Jazz Pharmaceuticals Ireland Limited

    Acute Myeloid Leukemia

    phase 3 small molecule terminated

    1 trial
  11. Gilteritinib

    The First People's Hospital of Lianyungang

    Acute Myeloid Leukemia (AML)

    phase 3 small molecule active

    1 trial
  12. HVA

    The First People's Hospital of Lianyungang

    Newly Diagnosed Acute Myeloid Leukemia With High Risk

    phase 3 small molecule active

    1 trial
  13. IAC regimen

    The First People's Hospital of Lianyungang

    Acute Myeloid Leukemia

    phase 3 small molecule completed

    1 trial
  14. Intermediate-dose Cytarabine in Combination with Venetoclax

    The First People's Hospital of Lianyungang

    Acute Myeloid Leukemia (AML)

    phase 3 small molecule active

    1 trial
  15. Iomab-B

    Actinium Pharmaceuticals

    Acute Myeloid Leukemia

    phase 3 small molecule active

    1 trial
  16. Mitoxantrone Hydrochloride Liposome

    The First People's Hospital of Lianyungang

    Acute Myeloid Leukemia (AML)

    phase 3 small molecule active

    1 trial
  17. Revumenib

    United Therapeutics Europe Ltd

    Acute Myeloid Leukemia, Adult

    phase 3 small molecule active

    1 trial
  18. Revumenib

    Syndax Pharmaceuticals

    Acute Myeloid Leukemias

    phase 3 small molecule active

    1 trial
  19. Sorafenib

    The First People's Hospital of Lianyungang

    Acute Myeloid Leukemia

    phase 3 small molecule completed

    1 trial
  20. Venetoclax

    The First People's Hospital of Lianyungang

    Acute Myeloid Leukemia

    phase 3 small molecule active

    1 trial
  21. Venetoclax 400

    United Therapeutics Europe Ltd

    Acute Myeloid Leukemia

    phase 3 small molecule active

    1 trial
  22. Ziftomenib

    Kura Oncology

    Acute Myeloid Leukemia (AML)

    phase 3 small molecule active

    1 trial
  23. gilteritinib

    Astellas Pharma Inc

    Acute Myeloid Leukemia (AML)

    phase 3 small molecule completed

    1 trial
  24. ADCT-301

    ADC Therapeutics SA

    Acute Myeloid Leukemia (AML)

    phase 2 small molecule terminated

    1 trial

Frequently asked questions

What is the Clinical Development Intelligence Platform?

It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.

How does this compare to Evaluate Pharma or Citeline?

Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.

Where does pipeline data come from?

Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.

Can I follow a company or program for updates?

Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.